Leukemia, lymphoma, and myeloma are among the hematologic malignancies that pose significant challenges to both patients and healthcare providers. Traditional treatments often come with debilitating side effects and limited efficacy.However, with the advent of Venetoclax Tablets, a new era of targeted therapy has emerged. Venclexta (venetoclax) tablets works by specifically targeting and inhibiting the BCL-2 protein, which plays a crucial role in promoting the survival of cancer cells. By blocking this protein, Venetoclax induces apoptosis, or programmed cell death, specifically in cancerous cells while sparing healthy ones.